Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXPEDITION-2
2015-005577-20Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Apr 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of glecaprevir and pibrentasvir in chronic hepatitis C (CHC) (2 arms), sponsored by AbbVie Inc. Primary endpoints: SVR12 and Safety. Started Apr 2016; status: completed.
02
Drugs
glecaprevirpibrentasvir
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on 2015-005577-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005577-20.